{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:26:43Z","timestamp":1772832403105,"version":"3.50.1"},"posted":{"date-parts":[[2024,9,2]]},"group-title":"In Review","reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,8,20]]},"abstract":"<title>Abstract<\/title>\n                <p>High-performance, resource-efficient methods for plasma amyloid-\u03b2 (A\u03b2) quantification in Alzheimer\u2019s disease are lacking; existing mass spectrometry-based assays are resource- and time-intensive. We developed a streamlined mass spectrometry method with a single immunoprecipitation step, an optimized buffer system, and \u226475% less antibody requirement. Analytical and clinical performances were compared with an in-house reproduced version of a well-known two-step assay. The streamlined assay showed high dilution linearity (r\u00b2&gt;0.99) and precision (&lt;\u200910% coefficient of variation), low quantification limits (A\u03b21\u201340: 12.5 pg\/ml; A\u03b21\u201342: 3.125 pg\/ml), and high signal correlation (r\u00b2~0.7) with the two-step immunoprecipitation assay. The novel single-step assay showed more efficient recovery of A\u03b2 peptides via fewer immunoprecipitation steps, with significantly higher signal-to-noise ratios, even at plasma sample volumes down to 50 \u00b5l. Both assays had equivalent performances in distinguishing non-elevated vs. elevated brain A\u03b2-PET individuals. The new method enables simplified yet robust evaluation of plasma A\u03b2 biomarkers in Alzheimer\u2019s disease.<\/p>","DOI":"10.21203\/rs.3.rs-4947448\/v1","type":"posted-content","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T09:28:59Z","timestamp":1725269339000},"source":"Crossref","is-referenced-by-count":6,"title":["A streamlined, resource-efficient immunoprecipitation-mass spectrometry method for quantifying plasma amyloid-\u03b2 biomarkers in Alzheimer's disease"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas","family":"Karikari","sequence":"first","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4579-4057","authenticated-orcid":false,"given":"Yijun","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Zeng","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Olvera-Rojas","sequence":"additional","affiliation":[{"name":"University of Granada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Sehrawat","sequence":"additional","affiliation":[{"name":"UPMC Children's Hospital Of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Lafferty","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9057-8014","authenticated-orcid":false,"given":"Tharick","family":"Pascoal","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Villemagne","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2493-9528","authenticated-orcid":false,"given":"Patricio","family":"Solis-Urra","sequence":"additional","affiliation":[{"name":"University of Granada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Trivi\u00f1o-Iba\u00f1ez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de las Nieves"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"G\u00f3mez-R\u00ed","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de las Nieves"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos","family":"Ikonomovic","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Esteban-Cornejo","sequence":"additional","affiliation":[{"name":"University of Granada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirk","family":"Erickson","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8546-8256","authenticated-orcid":false,"given":"Oscar","family":"Lopez","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Yates","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. Mankhong, S., et al., Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers. Biomedicines, 2022. 10(4).","DOI":"10.3390\/biomedicines10040850"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2. McKhann, G.M., et al., The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia, 2011. 7(3): p. 263\u2013269.","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Cummings, J., et al., Lecanemab: Appropriate Use Recommendations. The Journal of Prevention of Alzheimer's Disease, 2023.","DOI":"10.14283\/jpad.2023.30"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Rashad, A., et al., Donanemab for Alzheimer\u2019s Disease: A Systematic Review of Clinical Trials. Healthcare, 2022. 11(1): p. 32.","DOI":"10.3390\/healthcare11010032"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Dhillon, S., Aducanumab: First Approval. Drugs, 2021. 81(12): p. 1437\u20131443.","DOI":"10.1007\/s40265-021-01569-z"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Blennow, K., et al., Amyloid biomarkers in Alzheimer's disease. Trends in pharmacological sciences, 2015. 36(5): p. 297\u2013309.","DOI":"10.1016\/j.tips.2015.03.002"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Dubois, B., et al., Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement, 2016. 12(3): p. 292\u2013323.","DOI":"10.1016\/j.jalz.2016.02.002"},{"key":"ref8","unstructured":"8. Wang, M.J., et al., Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease. Alzheimer's Research & Therapy, 2017. 9(1): p. 98."},{"key":"ref9","unstructured":"9. Snyder, H.M., et al., Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement, 2014. 10(1): p. 109\u2009\u2212\u200914."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Janelidze, S., et al., Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Scientific Reports, 2016. 6(1): p. 26801.","DOI":"10.1038\/srep26801"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Weber, D.M., et al., Clinical utility of plasma A\u03b242\/40 ratio by LC-MS\/MS in Alzheimer\u2019s disease assessment. Frontiers in Neurology, 2024. 15: p. 1364658.","DOI":"10.3389\/fneur.2024.1364658"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Leuzy, A., et al., Blood-based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022. 14(1).","DOI":"10.15252\/emmm.202114408"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Zetterberg, H. and S.C. Burnham, Blood-based molecular biomarkers for Alzheimer\u2019s disease. Molecular Brain, 2019. 12(1): p. 26.","DOI":"10.1186\/s13041-019-0448-1"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Chong, J.R., et al., Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer\u2019s disease: a focused review on recent advances. Journal of Neurology, Neurosurgery & Psychiatry, 2021. 92(11): p. 1231\u20131241.","DOI":"10.1136\/jnnp-2021-327370"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Hampel, H., et al., Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape. Neuron, 2023. 111(18): p. 2781\u20132799.","DOI":"10.1016\/j.neuron.2023.05.017"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Karikari, T.K., Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance. J Alzheimers Dis, 2022. 90(3): p. 967\u2013974.","DOI":"10.3233\/JAD-215730"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Verberk, I.M.W., et al., Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol, 2018. 84(5): p. 648\u2013658.","DOI":"10.1002\/ana.25334"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. Janelidze, S., et al., Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimer's & Dementia, 2022. 18(2): p. 283\u2013293.","DOI":"10.1002\/alz.12395"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Palmqvist, S., et al., Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease\u2013Related \u03b2-Amyloid Status. JAMA Neurology, 2019. 76(9): p. 1060\u20131069.","DOI":"10.1001\/jamaneurol.2019.1632"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Thijssen, E.H., et al., Highly specific and ultrasensitive plasma test detects Abeta(1\u201342) and Abeta(1\u201340) in Alzheimer\u2019s disease. Scientific Reports, 2021. 11(1).","DOI":"10.1038\/s41598-021-89004-x"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Schindler, S.E., et al., High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology, 2019. 93(17): p. e1647-e1659.","DOI":"10.1212\/WNL.0000000000008081"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22. Nakamura, A., et al., High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature, 2018. 554(7691): p. 249\u2013254.","DOI":"10.1038\/nature25456"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"23. Jang, H., et al., Performance of the plasma A\u03b242\/A\u03b240 ratio, measured with a novel HPLC-MS\/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort. Alzheimer's Research & Therapy, 2021. 13(1).","DOI":"10.1186\/s13195-021-00911-7"},{"key":"ref24","unstructured":"24. Keshavan, A., et al., Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain : a journal of neurology, 2021. 144(2): p. 434\u2013449."},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. Iino, T., et al., Quantification of Amyloid-\u03b2 in Plasma by Simple and Highly Sensitive Immunoaffinity Enrichment and LC-MS\/MS Assay. J Appl Lab Med, 2021. 6(4): p. 834\u2013845.","DOI":"10.1093\/jalm\/jfaa225"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Brand, A.L., et al., The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimer's Research & Therapy, 2022. 14(1): p. 195.","DOI":"10.1186\/s13195-022-01117-1"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27. Teunissen, C.E., et al., Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. The Lancet Neurology, 2022. 21(1): p. 66\u201377.","DOI":"10.1016\/S1474-4422(21)00361-6"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. Ovod, V., et al., Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's & Dementia, 2017. 13(8): p. 841\u2013849.","DOI":"10.1016\/j.jalz.2017.06.2266"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29. Pannee, J., et al., The amyloid-\u03b2 degradation pattern in plasma\u2014A possible tool for clinical trials in Alzheimer's disease. Neuroscience Letters, 2014. 573: p. 7\u201312.","DOI":"10.1016\/j.neulet.2014.04.041"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Kaneko, N., et al., Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci, 2014. 90(9): p. 353\u2009\u2212\u200964.","DOI":"10.2183\/pjab.90.353"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"31. Hirtz, C., et al., Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer\u2019s disease diagnosis in a memory clinic cohort. Alzheimer's Research & Therapy, 2023. 15(1).","DOI":"10.1186\/s13195-023-01188-8"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"32. Chen, Y., et al., Effect of blood collection tube containing protease inhibitors on the pre-analytical stability of Alzheimer's disease plasma biomarkers. medRxiv, 2024.","DOI":"10.1101\/2024.03.05.24303504"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"33. Dey, K.K., et al., Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer\u2019s disease. Clinical Proteomics, 2019. 16(1): p. 16.","DOI":"10.1186\/s12014-019-9237-1"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"34. Solis-Urra, P., et al., Active Gains in brain Using Exercise During Aging (AGUEDA): protocol for a randomized controlled trial. Front Hum Neurosci, 2023. 17: p. 1168549.","DOI":"10.3389\/fnhum.2023.1168549"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"35. Zeng, X., et al., Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting. Molecular Neurodegeneration, 2024. 19(1).","DOI":"10.1186\/s13024-024-00711-1"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"36. Salvad\u00f3, G., et al., Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research & Therapy, 2019. 11(1): p. 27.","DOI":"10.1186\/s13195-019-0478-z"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"37. La Joie, R., et al., Multisite study of the relationships between <\u2009i\u2009>\u2009antemortem<\/i> [<\u2009sup\u2009>\u200911<\/sup\u2009>\u2009C]PIB-PET Centiloid values and <\u2009i\u2009>\u2009postmortem<\/i\u2009>\u2009measures of Alzheimer's disease neuropathology. Alzheimer's & Dementia, 2019. 15(2): p. 205\u2013216.","DOI":"10.1016\/j.jalz.2018.09.001"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"38. Akoglu, H., User's guide to correlation coefficients. Turk J Emerg Med, 2018. 18(3): p. 91\u201393.","DOI":"10.1016\/j.tjem.2018.08.001"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"39. Hu, Y., et al., Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. JAMA Network Open, 2022. 5(4): p. e228392.","DOI":"10.1001\/jamanetworkopen.2022.8392"},{"key":"ref40","unstructured":"40. Sperling, R.A., et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011. 7(3): p. 280\u2009\u2212\u200992."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"41. Jia, J., et al., Biomarker Changes during 20 Years Preceding Alzheimer\u2019s Disease. New England Journal of Medicine, 2024. 390(8): p. 712\u2013722.","DOI":"10.1056\/NEJMoa2310168"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"42. Mattke, S. and M. Hanson, Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States. Alzheimer's & Dementia, 2022. 18(5): p. 1071\u20131074.","DOI":"10.1002\/alz.12470"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"43. Rocca, M.F., et al., Utility of platforms Viteks MS and Microflex LT for the identification of complex clinical isolates that require molecular methods for their taxonomic classification. PLoS One, 2019. 14(7): p. e0218077.","DOI":"10.1371\/journal.pone.0218077"},{"key":"ref44","unstructured":"44. Food, U. and D. Administration, 510 (k) substantial equivalence determination decision summary. AlloMap\u00ae Molecular Expression Testing. K, 2013. 73482."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4947448\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4947448\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:06:15Z","timestamp":1771315575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4947448\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":44,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4947448\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41467-026-68372-w","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,9,2]]},"subtype":"preprint"}}